Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 127

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 127
---
 granted was estimated using the black Scholes model with the following assumptions:

| Description     |     |   2023 
 grants |
| Risk-free       
 interest rate   |     |  4.25% |
| Expected        
 volatility      |     | 115.5% |
| Dividend        
 yield           |     |     0% |
| Contractual     
 life (in years) |     |     10 |

On March 18, 2024, the Predecessor granted 3,000 options to purchase the Company's 3,000 Ordinary Shares to certain directors. 1,500 options vested on date of grant, 750 options will vest on September 18, 2024, and 750 options on March 18, 2025. The exercise price is $100 per share, and the options expire on March 18, 2034.

On May 12, 2024, the Predecessor granted 2,800 options to purchase Company's 2,800 Ordinary Shares to certain director. 1,400 options vested on date of grant, 700 options will vest on November 15, 2024, and 700 options on February 15, 2025. The exercise price is $100 per share, and the options expire on May 12, 2034.

On June 23, 2024, the Predecessor granted 2,800 options to purchase Company's 2,800 Ordinary Shares to certain director. 1,400 options vested on date of grant, 700 options will vest on November 15, 2024, and 700 options on February 15, 2025. The exercise price is $100 per share, and the options expire on June 23, 2034.

The aggregate grant date fair value of options granted in 2024 was approximately $808. The fair value of the Company’s share options granted was estimated using the black Scholes model with the following assumptions:

| Description     |     |     2024 
   grants |
| Risk-free       
 interest rate   |     |    4.34% 
  - 4.53% |
| Expected        
 volatility      |     |   111.8% 
 - 113.2% |
| Dividend        
 yield           |     |       0% |
| Contractual     
 life (in years) |     |       10 |

<div align='center'>F-20</div>

RE